Focused On-demand Library for Signal peptide peptidase-like 2B

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q8TCT7

UPID:
SPP2B_HUMAN

ALTERNATIVE NAMES:
Intramembrane protease 4; Presenilin homologous protein 4; Presenilin-like protein 1

ALTERNATIVE UPACC:
Q8TCT7; D6W609; O60365; Q567S3; Q8IUH9; Q9BUY6; Q9H3M4; Q9NPN2; Q9P1Z6

BACKGROUND:
The protein Signal peptide peptidase-like 2B, known alternatively as Intramembrane protease 4, Presenilin homologous protein 4, and Presenilin-like protein 1, functions as an intramembrane-cleaving aspartic protease. It is involved in the cleavage of type II membrane signal peptides and plays a significant role in the processing of ITM2B and TNF. This protein is instrumental in the intramembrane cleavage of the anchored fragment of shed TNF-alpha, facilitating intracellular domain signaling, and may contribute to the regulation of immune responses.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Signal peptide peptidase-like 2B could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.